Recursion Pharmaceuticals RXRX announced a significant investment worth $50 million from NVIDIA Corporation NVDA, a renowned technology company specializing in accelerated computing. This investment ...
SALT LAKE CITY, May 24, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced that Robert ...
On sci-fi TV shows like Star Trek, when a doctor needs to cure a disease, they often ask the computer to simulate complex visualizations or go through databases for potential cures. In real life, ...
Technology from computing powerhouse Nvidia is already hard at work inside companies at the convergence of technology and biology, including the supercomputer driving Recursion Pharmaceutical’s drug ...
Recursion Pharmaceuticals Stock Could Be a 10-Bagger, but Only if It Comes Through on This Big Claim
Recursion hopes to transform the healthcare industry with its innovative drug discovery platform. The small company has gained the interest of Nvidia, which has invested in the business. Together, the ...
Recursion Pharmaceuticals is merging with Exscientia. The new entity will have the backing of quite a few big names in pharma. It'll also have an even more capable drug discovery and development ...
Recursion Pharmaceuticals RXRX shares have gained 5.5% in a month. The stock gained momentum after the company announced the acquisition of Rallybio’s full stake in their joint venture earlier this ...
Recursion Pharmaceuticals, a drug discovery company that applies artificial intelligence to biology, is shoring up its technology platform by buying two startups that bolster its chemistry ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback